Get started
Author

F.J. Salvador Bofill

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
2022 · A. Prat, C. Falato, et al. · Annals of Oncology · 11
124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial
2023 · M. Oliveira, T. Pascual, et al. · ESMO Open · 8
PDF
296O Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+/HER2− BC: Preliminary analysis of the SOLTI-RIBOLARIS trial
2025 · P.H. Cottu, A. Prat, et al. · Annals of Oncology · 6
123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
2021 · P. Schmid, F.J. Salvador Bofill, et al. · Annals of Oncology · 6
PDF
LBA22 Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study
2025 · E. de Azambuja, P. Schmid, et al. · Annals of Oncology · 3
PDF
Assessment of Prognostic and Therapeutic Factors in Male Breast Cancer: An Observational Study of a Southwest Spanish Single Center
2020 · Daniel Herrero, María Rocío Morales Herrero, et al. · Archives of Breast Cancer · 3
Effectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study
2019 · J.E. Alés-Martínez, S. Morales, et al. · Annals of Oncology · 3
197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis
2023 · E.M. Ciruelos, P. Tolosa Ortega, et al. · ESMO Open · 2
195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancer
2025 · G. Villacampa, M. Oliveira, et al. · ESMO Open · 1
PDF
Abstract PO3-05-07: SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)
2024 · Eva Ciruelos, Cristina Saura, et al. · Cancer Research · 1
P119 Recurrence Score® result by the 21-gene assay before and after systemic neoadjuvant chemotherapy in patients with HR+ HER2-breast cancer.
2023 · N. Ciriaco, B. Vieites, et al. · The Breast · 1
PDF
202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
2022 · M. Oliveira, J.M. Cejalvo Andujar, et al. · Annals of Oncology · 1
57TiP SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
2022 · J. Balmana, T. Pascual, et al. · Annals of Oncology · 1
494P SOLTI-ATREZZO trial: Targeting PAM50 non-luminal HER2-positive advanced breast cancer (ABC) with atezolizumab, trastuzumab and vinorelbine (ATE+TRAS+VIN)
2026 · T. Pascual, F.J. Salvador Bofill, et al. · ESMO Open
520P Eribulin in her-2 negative metastatic breast cancer (mbc): Experience from a multicentric retrospective study across 15 Spanish Hospitals
2026 · J. Torres Sempere, D. Martin Sanchez, et al. · ESMO Open
388P Impact of prior therapy and hormone resistance on everolimus-exemestane efficacy in the post-CDK4/6 inhibitor era: A real-world study
2025 · P. Delgado Garces, M. Benavent Viñuales, et al. · ESMO Open
PDF
349P A new method to measure sexual satisfaction in metastatic breast cancer (SEXSAT-M)
2025 · J. Cruz Jurado, J.I. Chacon Lopez-Muniz, et al. · ESMO Open
PDF
Abstract PO3-05-06: Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
2024 · Mafalda Oliveira, Tomás Pascual, et al. · Cancer Research
Abstract PO1-27-07: Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative
2024 · Ana Gil-Torralvo, Yeray Rodriguez, et al. · Cancer Research
103P PET-CT in localized breast cancer: Does it impact on the therapeutic decision?
2024 · P. Macias Rodriguez, R. Buezas Perez, et al. · ESMO Open
PDF
265TiP SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer
2024 · E.M. Ciruelos, T. Pascual, et al. · ESMO Open
PDF
LBA3 SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC)
2024 · M. Oliveira, E.M. Ciruelos, et al. · ESMO Open
PDF
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
2023 · F. Brasó-Maristany, M. Oliveira, et al. · ESMO Open
PDF
146P Updated survival analysis in NEOPERSUR trial: Neoadjuvant pertuzumab in a real-world population in the south of Spain
2023 · A. Falcon Gonzalez, J. Cruz Jurado, et al. · ESMO Open
PDF
130P Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: Primary results of the SOLTI1710 PROMETEO II window of opportunity trial
2023 · S. Pernas Simon, E. Sanfeliu Torres, et al. · ESMO Open
PDF
Works count: 36
Citation count: 47
H-index: 4
I10-index: 1
Year
Topic
Type